Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19

Ann Pharmacother. 2023 Sep;57(9):1118-1119. doi: 10.1177/10600280221144936. Epub 2022 Dec 28.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • COVID-19 Drug Treatment
  • COVID-19*
  • Humans
  • Treatment Outcome

Substances

  • baricitinib
  • tocilizumab
  • Antibodies, Monoclonal, Humanized